Management of macular oedema in diabetic patients undergoing cataract surgery.
OBJECTIVE
The aim of this study was to describe all the treatment modalities used to prevent and manage macular oedema in diabetic patients undergoing cataract surgery.


RESULTS
Topical NSAIDs have been proposed to be an effective strategy to prevent postsurgical macular oedema (PME) in diabetic patients. The prophylactic use of intravitreal antivascular endothelial growth factors (anti-VEGF) drugs and steroids in these patients, even if effective, brings some concerns with regard to possible side effects. By contrast, in patients with a diagnosis of diabetic macular oedema (DME) at the time of cataract surgery, intravitreal therapy, both with anti-VEGF drugs and steroids, appears to be the best approach in order to control PME and achieve a good visual outcome.


CONCLUSIONS
All diabetic patients undergoing cataract surgery should be treated with topical NSAIDs to prevent PME. Intravitreal anti-VEGF drugs and steroids, combined with cataract surgery, should be reserved for patients with preexisting DME.
aDepartment of Surgical, Microsurgical and Medical Sciences, Ophthalmology Unit, University of Sassari bAzienda Ospedaliero Universitaria di Sassari, Sassari, Italy.
Francesco
F
Boscia
Ermete
E
Giancipoli
Giuseppe
G
D'Amico Ricci
Antonio
A
Pinna
D000287:Administration, Topical; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002387:Cataract Extraction; D003930:Diabetic Retinopathy / Q000150:complications*; D006801:Humans; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000517:prevention & control*; D009883:Ophthalmic Solutions; D011183:Postoperative Complications / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009883:Ophthalmic Solutions